1
|
Xu G, Torri D, Cuesta-Hoyos S, Panda D, Yates LRL, Zallot R, Bian K, Jia D, Iorgu AI, Levy C, Shepherd SA, Micklefield J. Cryptic enzymatic assembly of peptides armed with β-lactone warheads. Nat Chem Biol 2024; 20:1371-1379. [PMID: 38951647 PMCID: PMC11427300 DOI: 10.1038/s41589-024-01657-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/13/2023] [Accepted: 05/29/2024] [Indexed: 07/03/2024]
Abstract
Nature has evolved biosynthetic pathways to molecules possessing reactive warheads that inspired the development of many therapeutic agents, including penicillin antibiotics. Peptides armed with electrophilic warheads have proven to be particularly effective covalent inhibitors, providing essential antimicrobial, antiviral and anticancer agents. Here we provide a full characterization of the pathways that nature deploys to assemble peptides with β-lactone warheads, which are potent proteasome inhibitors with promising anticancer activity. Warhead assembly involves a three-step cryptic methylation sequence, which is likely required to reduce unfavorable electrostatic interactions during the sterically demanding β-lactonization. Amide-bond synthetase and adenosine triphosphate (ATP)-grasp enzymes couple amino acids to the β-lactone warhead, generating the bioactive peptide products. After reconstituting the entire pathway to β-lactone peptides in vitro, we go on to deliver a diverse range of analogs through enzymatic cascade reactions. Our approach is more efficient and cleaner than the synthetic methods currently used to produce clinically important warhead-containing peptides.
Collapse
Affiliation(s)
- Guangcai Xu
- Department of Chemistry and Manchester Institute of Biotechnology, The University of Manchester, Manchester, UK
| | - Daniele Torri
- Department of Chemistry and Manchester Institute of Biotechnology, The University of Manchester, Manchester, UK
| | - Sebastian Cuesta-Hoyos
- Department of Chemistry and Manchester Institute of Biotechnology, The University of Manchester, Manchester, UK
| | - Deepanjan Panda
- Department of Chemistry and Manchester Institute of Biotechnology, The University of Manchester, Manchester, UK
| | - Luke R L Yates
- Department of Chemistry and Manchester Institute of Biotechnology, The University of Manchester, Manchester, UK
| | - Rémi Zallot
- Department of Chemistry and Manchester Institute of Biotechnology, The University of Manchester, Manchester, UK
| | - Kehan Bian
- Department of Chemistry and Manchester Institute of Biotechnology, The University of Manchester, Manchester, UK
| | - Dongxu Jia
- Department of Chemistry and Manchester Institute of Biotechnology, The University of Manchester, Manchester, UK
| | - Andreea I Iorgu
- Department of Chemistry and Manchester Institute of Biotechnology, The University of Manchester, Manchester, UK
| | - Colin Levy
- Department of Chemistry and Manchester Institute of Biotechnology, The University of Manchester, Manchester, UK
| | - Sarah A Shepherd
- Department of Chemistry and Manchester Institute of Biotechnology, The University of Manchester, Manchester, UK
| | - Jason Micklefield
- Department of Chemistry and Manchester Institute of Biotechnology, The University of Manchester, Manchester, UK.
| |
Collapse
|
2
|
Muli CS, Trader DJ. 20S proteasome hydrolysis of LLVY substrates to determine preferences for moieties in its primed substrate channel. Bioorg Med Chem Lett 2023; 85:129233. [PMID: 36905968 PMCID: PMC10165662 DOI: 10.1016/j.bmcl.2023.129233] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/20/2023] [Revised: 03/03/2023] [Accepted: 03/07/2023] [Indexed: 03/13/2023]
Abstract
The proteasome is an essential multi-catalytic enzyme in cells that is responsible for degrading proteins with a ubiquitin-dependent or -independent mechanism. Many activity-based probes, inhibitors, and stimulators have been developed to study or modulate the activity of the proteasome. The development of these proteasome probes or inhibitors have been based on their interaction with the amino acids of the β5 substrate channel proceeding the catalytically active threonine residue. There is potential for positive interactions with a substrate to increase selectivity or cleavage rate with the β5 substrate channel after the catalytic threonine as evidenced by the proteasome inhibitor belactosin. To study what moieties the proteasome could accept in its primed substrate channel, we developed a liquid chromatography- mass spectrometry (LC-MS) method to quantitate the cleavage of substrates by purified human proteasome. This method allowed us to rapidly evaluate proteasome substrates that contain a moiety that could interact with the S1' site of the β5 proteasome channel. We were able to determine a preference for a polar moiety at the S1' substrate position. We believe this information can be used in the design of future inhibitors or activity-based probes for the proteasome.
Collapse
Affiliation(s)
- Christine S Muli
- Department of Medicinal Chemistry and Molecular Pharmacology, Purdue University, 575 West Stadium Avenue, West Lafayette, IN 47907, United States
| | - Darci J Trader
- Department of Medicinal Chemistry and Molecular Pharmacology, Purdue University, 575 West Stadium Avenue, West Lafayette, IN 47907, United States.
| |
Collapse
|
3
|
Viera CR, Stevens BT, Viera T, Zielinski C, Uranga LA, Rogelj S, Patidar PL, Tello-Aburto R. Cystargolide-based amide and ester Pz analogues as proteasome inhibitors and anti-cancer agents. ROYAL SOCIETY OPEN SCIENCE 2022; 9:220358. [PMID: 36177203 PMCID: PMC9515629 DOI: 10.1098/rsos.220358] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Figures] [Subscribe] [Scholar Register] [Received: 03/24/2022] [Accepted: 07/29/2022] [Indexed: 06/16/2023]
Abstract
A series of cystargolide-based β-lactone analogues containing nitrogen atoms at the Pz portion of the scaffold were prepared and evaluated as proteasome inhibitors, and for their cytotoxicity profile toward several cancer cell lines. Inclusion of one, two or even three nitrogen atoms at the Pz portion of the cystargolide scaffold is well tolerated, producing analogues with low nanomolar proteasome inhibition activity, in many cases superior to carfilzomib. Additionally, analogue 8g, containing an ester and pyrazine group at Pz, was shown to possess significant activity toward RPMI 8226 cells (IC50 = 21 nM) and to be less cytotoxic toward the normal tissue model MCF10A cells than carfilzomib.
Collapse
Affiliation(s)
- Carlos R. Viera
- Department of Chemistry, New Mexico Institute of Mining and Technology, Socorro, NM 87801, USA
| | - Bradley T. Stevens
- Department of Biology, New Mexico Institute of Mining and Technology, Socorro, NM 87801, USA
| | - Talysa Viera
- Department of Chemistry, New Mexico Institute of Mining and Technology, Socorro, NM 87801, USA
| | - Cameron Zielinski
- Department of Chemical Engineering, New Mexico Institute of Mining and Technology, Socorro, NM 87801, USA
| | - Lee A. Uranga
- Department of Chemistry and Biochemistry, New Mexico State University, Las Cruces, NM 88003, USA
| | - Snezna Rogelj
- Department of Biology, New Mexico Institute of Mining and Technology, Socorro, NM 87801, USA
| | - Praveen L. Patidar
- Department of Chemistry, New Mexico Institute of Mining and Technology, Socorro, NM 87801, USA
| | - Rodolfo Tello-Aburto
- Department of Chemistry and Biochemistry, New Mexico State University, Las Cruces, NM 88003, USA
| |
Collapse
|
4
|
Hubbell GE, Tepe JJ. Natural product scaffolds as inspiration for the design and synthesis of 20S human proteasome inhibitors. RSC Chem Biol 2020; 1:305-332. [PMID: 33791679 PMCID: PMC8009326 DOI: 10.1039/d0cb00111b] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/29/2020] [Accepted: 09/01/2020] [Indexed: 12/13/2022] Open
Abstract
The 20S proteasome is a valuable target for the treatment of a number of diseases including cancer, neurodegenerative disease, and parasitic infection. In an effort to discover novel inhibitors of the 20S proteasome, many reseaarchers have looked to natural products as potential leads for drug discovery. The following review discusses the efforts made in the field to isolate and identify natural products as inhibitors of the proteasome. In addition, we describe some of the modifications made to natural products in order to discover more potent and selective inhibitors for potential disease treatment.
Collapse
Affiliation(s)
- Grace E. Hubbell
- Department of Chemistry, Michigan State UniversityEast LansingMI 48823USA
| | - Jetze J. Tepe
- Department of Chemistry, Michigan State UniversityEast LansingMI 48823USA
| |
Collapse
|
5
|
Hewing B, Ludwig A, Dan C, Pötzsch M, Hannemann C, Petry A, Lauer D, Görlach A, Kaschina E, Müller DN, Baumann G, Stangl V, Stangl K, Wilck N. Immunoproteasome subunit ß5i/LMP7-deficiency in atherosclerosis. Sci Rep 2017; 7:13342. [PMID: 29042581 PMCID: PMC5645401 DOI: 10.1038/s41598-017-13592-w] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/30/2016] [Accepted: 08/17/2017] [Indexed: 12/23/2022] Open
Abstract
Management of protein homeostasis by the ubiquitin-proteasome system is critical for atherosclerosis development. Recent studies showed controversial results on the role of immunoproteasome (IP) subunit β5i/LMP7 in maintenance of protein homeostasis under cytokine induced oxidative stress. The present study aimed to investigate the effect of β5i/LMP7-deficiency on the initiation and progression of atherosclerosis as a chronic inflammatory, immune cell driven disease. LDLR-/-LMP7-/- and LDLR-/- mice were fed a Western-type diet for either 6 or 24 weeks to induce early and advanced stage atherosclerosis, respectively. Lesion burden was similar between genotypes in both stages. Macrophage content and abundance of polyubiquitin conjugates in aortic root plaques were unaltered by β5i/LMP7-deficiency. In vitro experiments using bone marrow-derived macrophages (BMDM) showed that β5i/LMP7-deficiency did not influence macrophage polarization or accumulation of polyubiquitinated proteins and cell survival upon hydrogen peroxide and interferon-γ treatment. Analyses of proteasome core particle composition by Western blot revealed incorporation of standard proteasome subunits in β5i/LMP7-deficient BMDM and spleen. Chymotrypsin-, trypsin- and caspase-like activities assessed by using short fluorogenic peptides in BMDM whole cell lysates were similar in both genotypes. Taken together, deficiency of IP subunit β5i/LMP7 does not disturb protein homeostasis and does not aggravate atherogenesis in LDLR-/- mice.
Collapse
Affiliation(s)
- Bernd Hewing
- Medizinische Klinik m.S. Kardiologie und Angiologie, Charité-Universitätsmedizin Berlin, Campus Mitte, Berlin, Germany
- DZHK (German Centre for Cardiovascular Research), partner site Berlin, Berlin, Germany
- Berlin Institute of Health (BIH), Berlin, Germany
| | - Antje Ludwig
- Medizinische Klinik m.S. Kardiologie und Angiologie, Charité-Universitätsmedizin Berlin, Campus Mitte, Berlin, Germany
- DZHK (German Centre for Cardiovascular Research), partner site Berlin, Berlin, Germany
| | - Cristian Dan
- Medizinische Klinik m.S. Kardiologie und Angiologie, Charité-Universitätsmedizin Berlin, Campus Mitte, Berlin, Germany
- DZHK (German Centre for Cardiovascular Research), partner site Berlin, Berlin, Germany
| | - Max Pötzsch
- Medizinische Klinik m.S. Kardiologie und Angiologie, Charité-Universitätsmedizin Berlin, Campus Mitte, Berlin, Germany
- DZHK (German Centre for Cardiovascular Research), partner site Berlin, Berlin, Germany
| | - Carmen Hannemann
- Medizinische Klinik m.S. Kardiologie und Angiologie, Charité-Universitätsmedizin Berlin, Campus Mitte, Berlin, Germany
- DZHK (German Centre for Cardiovascular Research), partner site Berlin, Berlin, Germany
| | - Andreas Petry
- Experimental and Molecular Pediatric Cardiology, German Heart Center Munich, Technical University Munich, Munich, Germany
- DZHK (German Centre for Cardiovascular Research), partner site Munich, Munich, Germany
| | - Dilyara Lauer
- Institute of Pharmacology, Center for Cardiovascular Research, Charité-Universitätsmedizin Berlin, Berlin, Germany
| | - Agnes Görlach
- Experimental and Molecular Pediatric Cardiology, German Heart Center Munich, Technical University Munich, Munich, Germany
- DZHK (German Centre for Cardiovascular Research), partner site Munich, Munich, Germany
| | - Elena Kaschina
- Institute of Pharmacology, Center for Cardiovascular Research, Charité-Universitätsmedizin Berlin, Berlin, Germany
| | - Dominik N Müller
- DZHK (German Centre for Cardiovascular Research), partner site Berlin, Berlin, Germany
- Experimental and Clinical Research Center, a joint cooperation of Max Delbrück Center for Molecular Medicine and Charité Medical Faculty, Berlin, Germany
- Berlin Institute of Health (BIH), Berlin, Germany
- Max Delbrück Center for Molecular Medicine in the Helmholtz Association, Berlin, Germany
| | - Gert Baumann
- Medizinische Klinik m.S. Kardiologie und Angiologie, Charité-Universitätsmedizin Berlin, Campus Mitte, Berlin, Germany
| | - Verena Stangl
- Medizinische Klinik m.S. Kardiologie und Angiologie, Charité-Universitätsmedizin Berlin, Campus Mitte, Berlin, Germany
- DZHK (German Centre for Cardiovascular Research), partner site Berlin, Berlin, Germany
| | - Karl Stangl
- Medizinische Klinik m.S. Kardiologie und Angiologie, Charité-Universitätsmedizin Berlin, Campus Mitte, Berlin, Germany
- DZHK (German Centre for Cardiovascular Research), partner site Berlin, Berlin, Germany
| | - Nicola Wilck
- Medizinische Klinik m.S. Kardiologie und Angiologie, Charité-Universitätsmedizin Berlin, Campus Mitte, Berlin, Germany.
- DZHK (German Centre for Cardiovascular Research), partner site Berlin, Berlin, Germany.
- Experimental and Clinical Research Center, a joint cooperation of Max Delbrück Center for Molecular Medicine and Charité Medical Faculty, Berlin, Germany.
- Max Delbrück Center for Molecular Medicine in the Helmholtz Association, Berlin, Germany.
| |
Collapse
|
6
|
α-Amino acids with electrically charged and polar uncharged side chains as chiral synthon: Application to the synthesis of bioactive alkaloids (1996-Dec, 2013). Tetrahedron 2017. [DOI: 10.1016/j.tet.2017.02.029] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/07/2023]
|
7
|
Jeon MK, Yi SJ, Son SU. Synthesis of Tetrasubstituted Thieno[3,2- b]pyridin-5(4 H)-one Derivatives as a Heterocyclic Scaffold for Multisite-specific Fluorous Fluorescent Tagging and Fluorous Solid-Phase Extraction. B KOREAN CHEM SOC 2016. [DOI: 10.1002/bkcs.10840] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022]
Affiliation(s)
- Moon-Kook Jeon
- Medicinal Chemistry Research Center; Bio & Drug Discovery Division, Korea Research Institute of Chemical Technology; Daejeon 305-600 Republic of Korea
| | - Su-Jin Yi
- Medicinal Chemistry Research Center; Bio & Drug Discovery Division, Korea Research Institute of Chemical Technology; Daejeon 305-600 Republic of Korea
- Department of Chemistry; Sungkyunkwan University; Suwon 440-746 Republic of Korea
| | - Seung Uk Son
- Department of Chemistry; Sungkyunkwan University; Suwon 440-746 Republic of Korea
| |
Collapse
|
8
|
Groll M, Korotkov VS, Huber EM, de Meijere A, Ludwig A. Ein minimales β-Lacton-Gerüst für selektive β5c- oder β5i-Proteasominhibitoren. Angew Chem Int Ed Engl 2015. [DOI: 10.1002/ange.201502931] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
|
9
|
Groll M, Korotkov VS, Huber EM, de Meijere A, Ludwig A. A Minimal β-Lactone Fragment for Selective β5c or β5i Proteasome Inhibitors. Angew Chem Int Ed Engl 2015; 54:7810-4. [PMID: 25973989 DOI: 10.1002/anie.201502931] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/30/2015] [Indexed: 11/09/2022]
Abstract
Broad-spectrum proteasome inhibitors are applied as anticancer drugs, whereas selective blockage of the immunoproteasome represents a promising therapeutic rationale for autoimmune diseases. We here aimed at identifying minimal structural elements that confer β5c or β5i selectivity on proteasome inhibitors. Based on the natural product belactosin C, we synthesized two β-lactones featuring a dimethoxybenzyl moiety and either a methylpropyl (pseudo-isoleucin) or an isopropyl (pseudo-valine) P1 side chain. Although the two compounds differ only by one methyl group, the isoleucine analogue is six times more potent for β5i (IC50=14 nM) than the valine counterpart. Cell culture experiments demonstrate the cell-permeability of the compounds and X-ray crystallography data highlight them as minimal fragments that occupy primed and non-primed pockets of the active sites of the proteasome. Together, these results qualify β-lactones as a promising lead-structure motif for potent nonpeptidic proteasome inhibitors with diverse pharmaceutical applications.
Collapse
Affiliation(s)
- Michael Groll
- Center for Integrated Protein Science at the Department Chemie, Technische Universität München, Lichtenbergstrasse 4, 85748 Garching (Germany).
| | - Vadim S Korotkov
- Center for Integrated Protein Science at the Department Chemie, Technische Universität München, Lichtenbergstrasse 4, 85748 Garching (Germany)
| | - Eva M Huber
- Center for Integrated Protein Science at the Department Chemie, Technische Universität München, Lichtenbergstrasse 4, 85748 Garching (Germany)
| | - Armin de Meijere
- Institut für Organische und Biomolekulare Chemie der Georg-August-Universität Göttingen, Tammannstrasse 2, 37077 Göttingen (Germany)
| | - Antje Ludwig
- Charité Universitätsmedizin Berlin CCM, Medizinische Klinik für Kardiologie und Angiologie, Charitéplatz 1, 10117 Berlin (Germany).
| |
Collapse
|
10
|
Gill KA, Berrué F, Arens JC, Carr G, Kerr RG. Cystargolides, 20S Proteasome Inhibitors Isolated from Kitasatospora cystarginea. JOURNAL OF NATURAL PRODUCTS 2015; 78:822-826. [PMID: 25769015 DOI: 10.1021/np501060k] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/04/2023]
Abstract
Two novel β-lactone-containing natural products, cystargolides A (1) and B (2), were isolated from the actinomycete Kitasatospora cystarginea. The production of these two natural products was highlighted using a methodology associating liquid chromatography-high-resolution mass spectrometry (LC-HRMS) analysis and the statistical analysis tool principal component analysis (PCA). Their structures were elucidated by interpretation of NMR experiments and tandem mass spectrometry. The absolute configurations of the amino acid residues were determined using Marfey's method, and the relative configurations of the β-lactone substituents were determined on the basis of the vicinal (3)J(HH) coupling value. Due to the presence of the β-lactone, 1 and 2 were evaluated for their ability to inhibit the human 20S proteasome. 1 and 2 both inhibited the 20S proteasome in vitro with IC50 values of 0.35 and 0.93 μM, respectively.
Collapse
Affiliation(s)
- Krista A Gill
- †Department of Chemistry, University of Prince Edward Island, 550 University Avenue, Charlottetown, PE, Canada C1A 4P3
| | - Fabrice Berrué
- †Department of Chemistry, University of Prince Edward Island, 550 University Avenue, Charlottetown, PE, Canada C1A 4P3
- ‡Nautilus Biosciences Canada Inc., DRC 550 University Avenue, Charlottetown, PE, Canada C1A 4P3
| | - Jennifer C Arens
- §Department of Biomedical Sciences, Atlantic Veterinary College, 550 University Avenue, Charlottetown, PE, Canada C1A 4P3
| | - Gavin Carr
- ‡Nautilus Biosciences Canada Inc., DRC 550 University Avenue, Charlottetown, PE, Canada C1A 4P3
| | - Russell G Kerr
- †Department of Chemistry, University of Prince Edward Island, 550 University Avenue, Charlottetown, PE, Canada C1A 4P3
- ‡Nautilus Biosciences Canada Inc., DRC 550 University Avenue, Charlottetown, PE, Canada C1A 4P3
- §Department of Biomedical Sciences, Atlantic Veterinary College, 550 University Avenue, Charlottetown, PE, Canada C1A 4P3
| |
Collapse
|
11
|
Voss C, Scholz C, Knorr S, Beck P, Stein ML, Zall A, Kuckelkorn U, Kloetzel PM, Groll M, Hamacher K, Schmidt B. α-Keto Phenylamides as P1′-Extended Proteasome Inhibitors. ChemMedChem 2014; 9:2557-64. [DOI: 10.1002/cmdc.201402244] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/12/2014] [Indexed: 12/14/2022]
|
12
|
Kawamura S, Unno Y, Asai A, Arisawa M, Shuto S. Development of a new class of proteasome inhibitors with an epoxyketone warhead: Rational hybridization of non-peptidic belactosin derivatives and peptide epoxyketones. Bioorg Med Chem 2014; 22:3091-5. [PMID: 24814885 DOI: 10.1016/j.bmc.2014.04.032] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/27/2014] [Revised: 04/15/2014] [Accepted: 04/15/2014] [Indexed: 01/18/2023]
Abstract
Proteasome inhibitors are currently a focus of increased attention as anticancer drug candidates. We recently performed systematic structure-activity relationship studies of the peptidic natural product belactosin A and identified non-peptidic derivative 2 as a highly potent proteasome inhibitor. However, the cell growth inhibitory effect of 2 is only moderate, probably due to the biologically unstable β-lactone warhead. Peptide epoxyketones are an important class of proteasome inhibitors exhibit high potency in cellular systems based on the efficient α,β-epoxyketone warhead. Importantly, belactosin derivatives bind primarily to the primed binding site, while peptide epoxyketones bind only to the non-primed binding site of proteasome, suggesting that hybridization of them might lead to the development of a new class of proteasome inhibitors. Thus, we successfully identified a novel chemotype of proteasome inhibitors 3 and 4 by rational structure-based design, which are expected to bind to both the primed and non-primed binding sites of proteasome.
Collapse
Affiliation(s)
- Shuhei Kawamura
- Faculty of Pharmaceutical Sciences, Hokkaido University, Kita-12, Nishi-6, Kita-ku, Sapporo 060-0812, Japan
| | - Yuka Unno
- Graduate School of Pharmaceutical Sciences, University of Shizuoka, Yada, Shizuoka 422-8526, Japan
| | - Akira Asai
- Graduate School of Pharmaceutical Sciences, University of Shizuoka, Yada, Shizuoka 422-8526, Japan
| | - Mitsuhiro Arisawa
- Graduate School of Pharmaceutical Sciences, Osaka University, 1-6 Yamada-oka, Suita, Osaka 565-0871, Japan
| | - Satoshi Shuto
- Faculty of Pharmaceutical Sciences, Hokkaido University, Kita-12, Nishi-6, Kita-ku, Sapporo 060-0812, Japan; Center for Research and Education on Drug Discovery, Hokkaido University, Kita-12, Nishi-6, Kita-ku, Sapporo 060-0812, Japan.
| |
Collapse
|
13
|
Micale N, Scarbaci K, Troiano V, Ettari R, Grasso S, Zappalà M. Peptide-Based Proteasome Inhibitors in Anticancer Drug Design. Med Res Rev 2014; 34:1001-69. [DOI: 10.1002/med.21312] [Citation(s) in RCA: 41] [Impact Index Per Article: 4.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/16/2022]
Affiliation(s)
- Nicola Micale
- Dipartimento di Scienze del Farmaco e dei Prodotti per la Salute; Università degli Studi di Messina; Viale Annunziata 98168 Messina Italy
| | - Kety Scarbaci
- Dipartimento di Scienze del Farmaco e dei Prodotti per la Salute; Università degli Studi di Messina; Viale Annunziata 98168 Messina Italy
| | - Valeria Troiano
- Dipartimento di Scienze del Farmaco e dei Prodotti per la Salute; Università degli Studi di Messina; Viale Annunziata 98168 Messina Italy
| | - Roberta Ettari
- Dipartimento di Scienze Farmaceutiche; Università degli Studi di Milano; Via Mangiagalli 25 20133 Milano Italy
| | - Silvana Grasso
- Dipartimento di Scienze del Farmaco e dei Prodotti per la Salute; Università degli Studi di Messina; Viale Annunziata 98168 Messina Italy
| | - Maria Zappalà
- Dipartimento di Scienze del Farmaco e dei Prodotti per la Salute; Università degli Studi di Messina; Viale Annunziata 98168 Messina Italy
| |
Collapse
|
14
|
Kawamura S, Unno Y, Asai A, Arisawa M, Shuto S. Structurally Novel Highly Potent Proteasome Inhibitors Created by the Structure-Based Hybridization of Nonpeptidic Belactosin Derivatives and Peptide Boronates. J Med Chem 2014; 57:2726-35. [DOI: 10.1021/jm500045x] [Citation(s) in RCA: 20] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/02/2023]
Affiliation(s)
| | - Yuka Unno
- Graduate
School of Pharmaceutical Sciences, University of Shizuoka, Yada, Shizuoka 422-8526, Japan
| | - Akira Asai
- Graduate
School of Pharmaceutical Sciences, University of Shizuoka, Yada, Shizuoka 422-8526, Japan
| | - Mitsuhiro Arisawa
- Graduate
School of Pharmaceutical Sciences, Osaka University, 1-6 Yamada-oka, Suita, Osaka 565-0871, Japan
| | | |
Collapse
|
15
|
Kawamura S, Unno Y, Hirokawa T, Asai A, Arisawa M, Shuto S. Rational hopping of a peptidic scaffold into non-peptidic scaffolds: structurally novel potent proteasome inhibitors derived from a natural product, belactosin A. Chem Commun (Camb) 2014; 50:2445-7. [DOI: 10.1039/c3cc48818g] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
Abstract
Rational scaffold hopping of a natural product belactosin A derivative based on the pharmacophore model constructed resulted in the identification of the significantly simplified highly potent non-peptide derivatives.
Collapse
Affiliation(s)
- Shuhei Kawamura
- Faculty of Pharmaceutical Sciences
- Hokkaido University
- Kita-ku, Japan
| | - Yuka Unno
- Graduate School of Pharmaceutical Sciences
- University of Shizuoka
- Shizuoka 422-8526, Japan
| | - Takatsugu Hirokawa
- Molecular Profiling Research Center for Drug Discovery (MOLPROF)
- National Institute of Advanced Industrial Science and Technology (AIST)
- Tokyo 135-0064, Japan
| | - Akira Asai
- Graduate School of Pharmaceutical Sciences
- University of Shizuoka
- Shizuoka 422-8526, Japan
| | - Mitsuhiro Arisawa
- Graduate School of Pharmaceutical Sciences
- Osaka University
- Suita, Japan
| | - Satoshi Shuto
- Faculty of Pharmaceutical Sciences
- Hokkaido University
- Kita-ku, Japan
- Center for Research and Education on Drug Discovery
- Hokkaido University
| |
Collapse
|
16
|
Kawamura S, Unno Y, List A, Mizuno A, Tanaka M, Sasaki T, Arisawa M, Asai A, Groll M, Shuto S. Potent Proteasome Inhibitors Derived from the Unnatural cis-Cyclopropane Isomer of Belactosin A: Synthesis, Biological Activity, and Mode of Action. J Med Chem 2013; 56:3689-700. [DOI: 10.1021/jm4002296] [Citation(s) in RCA: 38] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/19/2023]
Affiliation(s)
- Shuhei Kawamura
- Faculty of
Pharmaceutical Sciences, Hokkaido University, Kita-12, Nishi-6, Kita-ku, Sapporo
060-0812, Japan
| | - Yuka Unno
- Graduate
School of Pharmaceutical
Sciences, University of Shizuoka, Yada,
Shizuoka 422-8526, Japan
| | - Anja List
- Center for Integrated Protein
Science at the Department of Chemistry, Chair of Biochemistry, Technische Universität München, Lichtenbergstrasse
4, 85747 Garching, Germany
| | - Akirai Mizuno
- Faculty of
Pharmaceutical Sciences, Hokkaido University, Kita-12, Nishi-6, Kita-ku, Sapporo
060-0812, Japan
| | - Motohiro Tanaka
- School of Pharmacy, Aichi Gakuin
University, 1-100 Kusumoto-cho, Chikusa-ku, Nagoya 464-8650, Japan
| | - Takuma Sasaki
- School of Pharmacy, Aichi Gakuin
University, 1-100 Kusumoto-cho, Chikusa-ku, Nagoya 464-8650, Japan
| | - Mitsuhiro Arisawa
- Faculty of
Pharmaceutical Sciences, Hokkaido University, Kita-12, Nishi-6, Kita-ku, Sapporo
060-0812, Japan
| | - Akira Asai
- Graduate
School of Pharmaceutical
Sciences, University of Shizuoka, Yada,
Shizuoka 422-8526, Japan
| | - Michael Groll
- Center for Integrated Protein
Science at the Department of Chemistry, Chair of Biochemistry, Technische Universität München, Lichtenbergstrasse
4, 85747 Garching, Germany
| | - Satoshi Shuto
- Faculty of
Pharmaceutical Sciences, Hokkaido University, Kita-12, Nishi-6, Kita-ku, Sapporo
060-0812, Japan
| |
Collapse
|
17
|
Rentsch A, Landsberg D, Brodmann T, Bülow L, Girbig AK, Kalesse M. Synthese und Pharmakologie von Proteasom-Inhibitoren. Angew Chem Int Ed Engl 2013. [DOI: 10.1002/ange.201207900] [Citation(s) in RCA: 20] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/19/2022]
|
18
|
Rentsch A, Landsberg D, Brodmann T, Bülow L, Girbig AK, Kalesse M. Synthesis and pharmacology of proteasome inhibitors. Angew Chem Int Ed Engl 2013; 52:5450-88. [PMID: 23526565 DOI: 10.1002/anie.201207900] [Citation(s) in RCA: 76] [Impact Index Per Article: 6.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/30/2012] [Indexed: 12/17/2022]
Abstract
Shortly after the discovery of the proteasome it was proposed that inhibitors could stabilize proteins which ultimately would trigger apoptosis in tumor cells. The essential questions were whether small molecules would be able to inhibit the proteasome without generating prohibitive side effects and how one would derive these compounds. Fortunately, "Mother Nature" has generated a wide variety of natural products that provide distinct selectivities and specificities. The chemical synthesis of these natural products finally provided access to analogues and optimized drugs of which two different classes have been approved for the treatment of malignancies. Despite these achievements, additional lead structures derived from nature are under investigation and will be discussed with regard to their biological potential and chemical challenges.
Collapse
Affiliation(s)
- Andreas Rentsch
- Institut für Organische Chemie and Centre of Biomolecular Drug Research, Leibniz Universität Hannover, Schneiderberg 1B, 30167 Hannover, Germany
| | | | | | | | | | | |
Collapse
|
19
|
Kawamura S, Unno Y, Asai A, Arisawa M, Shuto S. Design and synthesis of the stabilized analogs of belactosin A with the unnatural cis-cyclopropane structure. Org Biomol Chem 2013; 11:6615-22. [DOI: 10.1039/c3ob41338a] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/30/2022]
|
20
|
de Meijere A, Korotkov VS, Lygin AV, Larionov OV, Sokolov VV, Graef T, Es-Sayed M. Synthesis and biological activity of simplified belactosin C analogues. Org Biomol Chem 2012; 10:6363-74. [DOI: 10.1039/c2ob25586c] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
|